Estradiol-16α-carboxylic Acid Esters as Locally Active Estrogens

David C. Labaree, Toni Y. Reynolds, and Richard B. Hochberg*
Department of Obstetrics and Gynecology, and Comprehensive Cancer Center, Yale University School of Medicine, New Haven, Connecticut 06520
J. Med. Chem., 2001, 44 (11), pp 1802–1814
DOI: 10.1021/jm000523h
Publication Date (Web): April 27, 2001
Copyright © 2001 American Chemical Society
*

 Corresponding author. Phone:  (203)785-4001. Fax:  (203)737-4391. E-mail:  richard.hochberg@yale.edu.

,

 Department of Obstetrics and Gynecology.

Abstract

Abstract Image

We attempted to design analogues of estradiol to act as locally active estrogens without significant systemic action. We synthesized a series of 16α-carboxylic acid substituted steroids and their esters and tested their action in several assays of estrogenic action, including estrogen receptor (ER) binding, estrogenic potency in Ishikawa cells (human endometrial carcinoma), rat uterine weight (systemic action), and mouse vaginal reductases (local action). All of the estradiol substituted carboxylic acids (formic, acetic and propionic acids) were devoid of estrogenic action. To the contrary, many of the esters had marked estrogenic potency in the receptor and the Ishikawa assays. The esters of the 16α-formic acid series had the highest ER affinity with little difference between the straight-chain alcohol esters (from methyl to n-butyl). However, estrogenic action in the Ishikawa assay decreased precipitously with esters longer than the ethyl ester. This decrease correlated well with the increased rate of esterase hydrolysis of longer esters as determined in incubations with rat hepatic microsomes. The most promising candidates, the methyl, ethyl, and fluoroethyl esters of the formate series, were tested for systemic and local action in the in vivo models. All three, especially the fluoroethyl ester, showed divergence between systemic and local estrogenic action. These metabolically labile estrogens will be extremely useful for the therapeutic treatment of the vaginal dyspareunia of menopause in women for whom systemic estrogens are contraindicated.

Tools

History

  • Published In Issue May 24, 2001
  • Received December 7, 2000

Recommend & Share

Related Content

Other ACS content by these authors: